10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

cIAP2 (BIRC3) Antibody (N-term) Blocking peptide
Synthetic peptide
Catalog # BP6124a

Specification

cIAP2 (BIRC3) Antibody (N-term) Blocking peptide - Product Information

Primary Accession	Q13489
Other Accession	NP_892007

cIAP2 (BIRC3) Antibody (N-term) Blocking peptide - Additional Information

Gene ID 330

Other Names
Baculoviral IAP repeat-containing protein 3, 632-, Apoptosis inhibitor 2, API2, C-IAP2, IAP homolog C, Inhibitor of apoptosis protein 1, IAP-1, hIAP-1, hIAP1, RING finger protein 49, TNFR2-TRAF-signaling complex protein 1, BIRC3, API2, IAP1, MIHC, RNF49

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP6124a was selected from the N-term region of human BIRC3 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

cIAP2 (BIRC3) Antibody (N-term) Blocking peptide - Protein Information

Name BIRC3

Synonyms API2, MIHC, RNF49

Function
Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non- canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and

BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase- independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8.

Cellular Location
Cytoplasm. Nucleus

Tissue Location
Highly expressed in fetal lung, and kidney. In the adult, expression is mainly seen in lymphoid tissues, including spleen, thymus and peripheral blood lymphocytes

cIAP2 (BIRC3) Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

cIAP2 (BIRC3) Antibody (N-term) Blocking peptide - Images

cIAP2 (BIRC3) Antibody (N-term) Blocking peptide - Background

BIRC3 is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2, probably by interfering with activation of ICE-like proteases. The encoded protein inhibits apoptosis induced by serum deprivation but does not affect apoptosis resulting from exposure to menadione, a potent inducer of free radicals. The amino acid sequence predicts three baculovirus IAP repeat domains and a ring finger domain.

cIAP2 (BIRC3) Antibody (N-term) Blocking peptide - References

Wang, Q., et al., J. Biol. Chem. 278(51):51091-51099 (2003).Suguro-Katayama, M., et al., Leukemia 17(12):2508-2512 (2003).Jonsson, G., et al., Anticancer Res. 23(4):3311-3316 (2003).Yang, Q.H., et al., Genes Dev. 17(12):1487-1496 (2003).Dai, Z., et al., Hum. Mol. Genet. 12(7):791-801 (2003).